DEFA14A: BioAffinity Corrects Outstanding Share Count for Special Meeting
Proxy Statement Supplement
BioAffinity Technologies, Inc. issued a supplement to its proxy statement to correct a clerical error in the number of outstanding common shares for its upcoming Special Meeting.
Summary
- BioAffinity Technologies, Inc. filed a supplement to its proxy statement, originally filed on November 7, 2025, for the Special Meeting of Stockholders.
- The purpose of the supplement is to correct a clerical error regarding the number of shares of common stock outstanding as of the Record Date, November 4, 2025.
- The previously stated number of outstanding shares was 3,633,815, which has been corrected to 4,498,709 shares of common stock.
- All 4,498,709 shares are entitled to vote at the Special Meeting scheduled for December 19, 2025.
- The correction does not change the proposals to be acted upon at the Special Meeting.
- Any changes to the percentage ownership of the company's directors, executive officers, and five percent stockholders, as a result of this correction, are considered immaterial.
Sentiment
Score: 5
Explanation: The filing is a factual correction of a clerical error regarding outstanding shares, with no direct positive or negative operational or financial news. The impact on beneficial ownership percentages is stated as immaterial.
Negatives
- A clerical error led to an incorrect reporting of outstanding shares in the initial proxy statement, indicating a minor administrative oversight.
Risks
- The initial clerical error in reporting outstanding shares could raise minor concerns about data accuracy in regulatory filings, though it has been corrected.
Future Outlook
This filing is a factual correction and does not contain forward-looking statements or guidance regarding the company's future operations or financial performance.
Industry Context
This announcement is a company-specific procedural correction to a proxy statement and does not reflect broader industry trends or competitive dynamics.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Correction | Correction of a clerical error in the number of outstanding common shares, ensuring accurate information for shareholder voting and ownership calculations. | 2025-11-12 | Enhances transparency and accuracy of corporate disclosures, which is fundamental to good corporate governance, though the initial error represents a minor lapse. |
Stakeholder Impact
- Shareholders: Provided with corrected information regarding the total number of outstanding shares, which is crucial for understanding voting power and ownership percentages. The impact on individual beneficial ownership percentages is stated as immaterial.
Next Steps
- Stockholders who have already voted do not need to vote again unless they wish to change or revoke their prior vote.
- The Special Meeting of Stockholders will proceed as scheduled on December 19, 2025.
Key Dates
| Date | Description |
|---|---|
| 2025-11-04 | Record Date for determining stockholders entitled to vote at the Special Meeting. |
| 2025-11-07 | Original Proxy Statement filed with the U.S. Securities and Exchange Commission. |
| 2025-11-12 | Date of this Supplement to the Proxy Statement. |
| 2025-12-19 | Date of the Special Meeting of Stockholders. |
Keywords
bioAffinity Technologies, proxy statement, outstanding shares, common stock, special meeting, SEC filing, DEFA14A, shareholder vote
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.